

CURRICULUM VITAE

Mark C. Scholz, MD

4676 Admiralty Way, Suite 101
Marina del Rey, CA 90292
T: 310 827 7707 F: 310 574 4002
E: mark@prostateoncology.com
W: prostateoncology.com
pcri.org
markscholz.com

Licensure	Medical Board of California, 1984, G52827
Certifications	American Board of Internal Medicine, 1986 American Board of Medical Oncology, 1989
NPI	1588653943
DEA	AS2791552
Foreign Languages	Spanish

EDUCATION:

Fellowship	Medical Oncology, 1986-1988 Chief Fellow, 1987-1988 LAC-USC Medical Center, Los Angeles
Residency	Internal Medicine, 1984-1986 LAC-USC Medical Center, Los Angeles
Internship	Internal Medicine, 1983-1984 LAC-USC Medical Center, Los Angeles
Medical School	Creighton University, 1983
College/University	Orange Coast College, 1973-1974 University of Southern California, 1974-1976 Occidental College, 1976-1978
High School	Corona del Mar, 1969-1973

PROFESSIONAL BACKGROUND:

Administrative Responsibilities

Executive Director, Prostate Cancer Research Institute, Los Angeles, 2006 to present

Oncology Director, Daniel Freeman Medical Center, Marina del Rey, 1996-2001

Co-Founder and Past President, Prostate Cancer Research Institute, Los Angeles, 1996-1999

Oncology Director Medical Center of North Hollywood, 1993-1994

Oncology Director, Mullikin Medical Center, Cerritos, 1988-1990

Present Employment

Medical Director, Prostate Oncology Specialists, Inc., Marina del Rey

Expert Oncology Witness:
Case Reviews: 80 cases
Depositions: 17 cases
Court Testimony: 7 cases

Editorial Responsibilities

Consultant:
Cancer
Clinical Genitourinary Cancer
Journal of Clinical Oncology
Journal of Urology

Editor for *PCRI Insights* newsletter

Task Force for Androgen Independent PC

Society Memberships

American College of Physicians
American Medical Association
American Medical Society
American Society of Clinical Oncology
American Society of Therapeutic Radiology
American Urological Association
American Urological Association, Affiliate
California Medical Society
European Association of Urology
Los Angeles County Medical Association

Hospital Affiliations

Marina del Rey Hospital, Marina del Rey
Motion Picture Hospital, Canoga Park
Saint John's Hospital, Santa Monica

Other Responsibilities

Steering Committee of the Bereavement Project at Concordia University
Steering Committee for Minority Involvement in Clinical Trials at USC

Clinical Trials

Principal Investigator

10TASQ10: A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men Metastatic Castrate Resistant Prostate Cancer.

212082PCR3001: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed after Taxane-based Chemotherapy.

9785-CL-0401: A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

ABT627: A Phase II/III Extension study to Evaluate the Safety and Tolerability of Atrasentan.

BMS184-043: A Randomized, Double-blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that Have Received Prior Treatment with Docetaxel.

BMS184-095: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer.

CC-5013-PC-002: A Phase III Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenolidomide in Subjects with Castrate-Resistant Prostate Cancer.

COU-AA-301: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.

COU-AA-302: A Phase III, Randomized, Double-blind, Placebo-controlled study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer.

CRPC2: A Multinational Phase III, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy.

EN99-01: A Phase II Study to Determine the Effectiveness of Pecta-Sol in Prostate Cancer.

MDV3100-09: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy.

OGX-011-11: A Randomized Phase III Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custersin (OGX-011) in Men with Metastatic Castrate-Resistant Prostate Cancer.

OGX-011-12: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY).

P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer.

P11-3: A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC).

P11-4 PRIME: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

SIPIPI 2013: Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer.

TAX-327: A Multicenter Phase III Randomized Trial Comparing Docetaxel Administered Either Weekly or Every Three Weeks in Combination with Prednisone Versus Mitoxantrone in Combination with Prednisone for Metastatic Hormone Refractory Prostate Cancer.

XL184-306: A Phase III, Randomized, Double-blind, Controlled Trial of Cabzantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Sub-Investigator

CRITICAL-001: A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy with Autologous Immature Dendritic Cells (VCD2008) in Chemo-naïve Men with Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone.

Speaker Bureau

Sanofi-Aventis: Jevtana
Cytogen Corporation
Dendreon Corporation: Provenge
Amgen Corporation: Xgeva
Medivation: Xtandi

Editorial Board

Medivation: MDV3100
Bristol Meyers Squibb: Ipilimumab and Dasatinib
Johnson and Johnson: Abiraterone Acetate

Advisory Board

Amgen
Bayer HealthCare Pharmaceuticals

Bristol Meyers Squibb
Centocor Ortho Biotech
Dendreon
Medivation

Bibliography

Scholz, M. C., Groom, M.K., Kaddis, A.J., Strum, S.B., Jennrich, R.I., Bahn, D.K., Chang, P.J., Becker, L.K. and Lam, R. Y., "Primary Androgen Deprivation (AD) Followed by Active Surveillance (AS) for Newly Diagnosed Prostate Cancer (PC): A Retrospective Study." *Prostate*, 73: 83-88 (2013).

Scholz, M., "Comparative Analysis of Prostate-Specific Antigen Free Survival Outcomes for Patients with Low, Intermediate and High Risk Prostate Cancer Treatment by Radical Therapy. Results from the Prostate Cancer Results Study Group." *BJUI* Vol. 109, Issue Supplement s1 February 2012).

Scholz, M., Lam, R., Strum, S., LaBarba, D., Becker, L., Chang, P. and et al. "Primary Intermittent Androgen Deprivation as Initial Therapy for Men with Newly Diagnosed Prostate Cancer." *Clinical Genitourinary Cancer*, Vol. 9, No. 2 (2011): 89-94.

Scholz, M., Lam, R., Strum, S., LaBarba, D., Becker, L., Chang, P. and et al. "Primary Intermittent Androgen Deprivation as Initial Therapy for Men with Newly Diagnosed Prostate Cancer." *Clinical Genitourinary Cancer*, Vol. 9, No. 2 (2011): 89-94.

Scholz, M., "Abiraterone and Increased Survival in Metastatic Prostate Cancer." *NEJM* (May 26, 2011).

Scholz, M., Lam, R., Jennrich, R., Strum, S., Johnson, H., and T. Trilling. "Prostate Cancer-Specific Survival and Clinical Progression-Free Survival in Men with Prostate Cancer Treated Intermittently with Testosterone Inactivating Pharmaceuticals." *Urology* 70 (2007): 506.

Scholz, M., Lam, R., and L. Klotz. "Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men." *JAMA* 297 (2007):1651-1652. (Letter).

Shaw, G., Cuzick, J., Goldenberg, L., Spry, N., Prapotnich, D., Malone, S., Foran, J., Scholz, M., Albrecht, W., and T. Oliver. "Pragmatic Recommendation and Directions for Future Work Base on a Meta-Analysis of 1653 Patients treated with Intermittent Hormone Therapy (IHT) for Adenocarcinoma of the Prostate." *Journal of Urology* 68 Supplement 3 (2006): 5A.

Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., and R.Y. Lam. "Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period." *Journal of Urology* 175 (2006):1673.

Guess, B., Scholz, M., and R. Lam. "Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer." *Seminars in Preventative and Alternative Medicine* (2006).

Scholz, M., Jennrich, R., Strum, S., Brosman, S., Johnson, H., and R. Lam. "Long-Term Outcome for Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone." *Journal of Urology* 173 (2005).

Guess, B., Scholz, M., Strum, S., Lam, R., Johnson, H., and R. Jennrich. "Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study" *Prostate Cancer and Prostatic Diseases* 6 (2003): 301-304.

Scholz, M., Strum, S., Berrios, F., Leibowitz, B., and B. Guess. "Low-Dose Single-Agent Weekly Docetaxel (Taxotere) is Effective and Well Tolerated in Elderly Men with Prostate Cancer." *Advances in Prostate Cancer* 5, no. 3 (2001).

Guess, B., and M. Scholz. "RE: Failure to Achieve Castrate Levels of Testosterone During Luteinizing Hormone Releasing Hormone Agonist Therapy: The Case for Monitoring Serum Testosterone and a Treatment Decision Algorithm." Letter to the Editor, *Journal of Urology* 165 (2001): 1644-1645.

Scholz, M., and S. Strum. "RE: Prostate Specific Antigen: A Decade of Discovery—What We Have Learned and Where we are Going." Letter to the Editor, *Journal of Urology* 163 (2000): 1259-1260.

Strum, S., Scholz, M., and J. McDermed. "Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time off Therapy." *The Oncologist* 5 (2000).

Guess B., Jennrich, R., Johnson, H., Redheffer, R., and M. Scholz. "Using Splines to Detect Changes in PSA Doubling Times." *Prostate* 54, no. 2 (1999): 88-94.

Scholz, M., and S. Strum. "RE: Recovery of Spontaneous Erectile Function After Nerve-Sparing Radical Retropubic Prostatectomy With and Without Early Intracavernous Injections of Alprostadil." Letter to the Editor, *Journal of Urology* 161 (1999): 1914-1915.

Strum, S., McDermed, J., Scholz, M., Johnson, H., and G. Tisman. "Anemia Associated with Androgen Deprivation in Patients with Prostate Cancer Receiving Combination Hormone Blockade." *British Journal of Urology* 8 (June 1997).

Gill, I., Gurglianone, P., Grunberg, S. M., Scholz, M. C., and F. M. Muggia. "High Dose Intensity of Cisplatin and Etoposide in Adenocarcinoma of Unknown Primary." *Anticancer Research* 2 (1991): 1231.

Other Publications:

Scholz, M., "Report from The Annual Meeting of Radiation Therapists." *PCRI Insights*, Vol. 16: no.4 (November 2013).

Scholz, M., "So Many New Things in 2013 PCRI Conference." *PCRI Insights*, Vol. 16: no.4 (November 2013).

Scholz, M., "Lunch with Ryan O'Neal and Duke Bahn, MD." *PCRI Insights*, Vol. 16: no. 3 (August 2013).

Scholz, M., "New Studies Presented at the ASCO and AUA Annual Meetings." *PCRI Insights*, Vol. 16: no. 3 (August 2013).

Scholz, M., "The Big Picture about Men's Health: It's not just about the prostate." *VitaJournal* (July 2013).

Scholz, M., "The 2013 ASCO Genitourinary Conference in Review." *PCRI Insights*, Vol. 16: no. 2 (May 2013).

Scholz, M., "Royal: The Fifth Shade of Blue." *PCRI Insights*, Vol. 15, no. 2 (May 2012).

Scholz, M., "INDIGO: The Fourth Shade." *PCRI Insights*, Vol. 15, no. 1 (February 2012).

Scholz, M., "Summary: 2012 Genitourinary Cancers Symposium." *PCRI Weekly*, Vol 1, Issue 8 (February 9, 2012).

- Scholz, M., "Unnecessary Scanning of Low-Risk Patients." *PCRI Weekly*, Vol. 1, Issue 7 (January 26, 2012).
- Scholz, M., "Temporary Seeds are Effective for Men in the "Teal" Shade." *PCRI Weekly*, Vol. 1, Issue 6 (January 19, 2012).
- Scholz, M., "Dying from Prostate Cancer: Less Risky Than You May Think." *PCRI Weekly*, Vol. 1, Issue 5 (January 12, 2012).
- Scholz, M., "Testosterone Flare: Is it a Concern?" *PCRI Weekly*, Vol. 1, Issue 4 (January 5, 2012).
- Scholz, M., "With Radiation, Prostate Size Matters; Urinary Retention After Seed Implants Depends on Several Factors." *PCRI Weekly* Vol. 1, Issue 3 (December 22, 2011).
- Scholz, M., "Denosumab Prevents Bone Metastasis." *PCRI Weekly*, Vol. 1, Issue 2 (December 15, 2011).
- Scholz, M., "How Much Hormone Blockade is Best?" *PCRI Weekly* Vol. 1, Issue 1 (December 8, 2011).
- Scholz, M. "What's Your Shade?" *PCRI Insights* Vol 14: no. 4 (November 2011).
- Scholz, M., "Cabozantinib (XL184)." *PCRI Insights* Vol. 14, no. 2 (May 2011).
- Scholz, M., "Urological Society Meeting Abstracts May, 2011." *PCRI Insights* Vol. 14, no. 2 (May 2011).
- Scholz, M., "Testosterone Inactivating Pharmaceuticals." *PCRI Insights* Vol. 13, no. 4 (November 2010).
- Scholz, M., "Prostate Surgery can Lead to Impotency." *TopNews* (August 9, 2010). (accessed June 23, 2011).
- Scholz, M., "Conference Highlights 2007/2008 from The ASCO Genitourinary Cancers Symposium, the Prostate Cancer Foundation Scientific Retreat, and the Upcoming American Urological Association Meeting *PCRI Insights*." Vol. 11, no. 2 (May 2008)
- Scholz, M., Bahn, D., and R. Lam. "Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it Foolproof?" *PCRI Insights* 10, no. 1 (February 2007).
- Scholz, M., Blum, R., "Can Diet Really Impact Prostate Cancer?" *PCRI Insights* Vol. 10, no. 1 (February 2007).
- Scholz, M. "Preventing Prostate Cancer through Diet." *Healthy Aging* (July/August 2006).
- Scholz, M., Lam, R., Guess, B., and R. Blum. "When Should You Start Treatment with Ketoconazole?" *PAACT* 21, no. 4 (December 2005).
- Scholz, M., Blum, R., "Who is Really at Risk for What?" *PCRI Insights* Vol. 8, no. 2 (May 2005).
- Scholz, M., Blum, R., "Laboratory Tests Defined." *PCRI Insights* Vol. 8, no. 2 (May 2005).
- Scholz, M. "Clear Controversy: Prostate Cancer: The (not so) Simple Facts." *My Family Doctor* (Winter 2005).

Scholz, M., "The Way to Find the Best Available Treatment for Your PC: Advice for Men Newly Diagnosed with Prostate Cancer." *PCRI Insights* 7, no. 3 (August 2004).

Scholz, M., "Newly Diagnosed Prostate Cancer: Evaluating the Option – Part 3 of 3." *PCRI Insights* Vol. 7, no. 1 (February 2004).

Scholz, M., "Newly Diagnosed Prostate Cancer: Evaluating the Options – Part 2 of 3." *PCRI Insights* Vol. 6, no. 3 (August 2003).

Scholz, M., "Newly Diagnosed Prostate Cancer: Evaluating the Options – Part 1 of 3." *PCRI Insights* Vol. 6, no. 1 (February 2003).

Scholz, M., Lam, R., and B. Guess. "Anti-androgen Monotherapy for Prostate Cancer." *PAACT* 18, no. 2. (June 2002).

Scholz, M. "New Approaches to Prostate Cancer Treatment." *Prostate Cancer Battle: It's Strictly Your Decision Olympic Blazes Trail to Solution*. 1st Books Library, (March 2002).

Scholz, M. "Early Hormone Blockade for Men Suitable for Local Therapy." *Prostate Cancer Battle: It's Strictly Your Decision*. 1st Books Library, (March 2002).

Abstracts and Posters

Crawford, E.D., Scholz, M., Kar, A., Fegan, J., Haregewoin, A., Kaldate, R., and M. Brawer. "Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry." Abstract. *Current Medical Research & Opinion* (CMRO) (2014).

Scholz, M., "Safety results of the enzalutamide expanded access program in the U.S. and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel." Abstract. ASCO-GU (2014)

Scholz, M., "Cell cycle progression (CCp) score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial." Abstract. ASCO-GU (2014)

Scholz, M., "Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED." Abstract. ASCO-GU (2013).

Scholz, M., "Experience with sipuleucel-t (Sip-T) in a community oncology clinic: Initial 50 patients (pts)." Abstract. ASCO-GU (2012).

Scholz, M., "Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy." Results from the Prostate Cancer Results Study Group." Abstract. *BJU International* (2012): Vol. 109.

Scholz, M., "Abiraterone and Increased Survival in Metastatic Prostate Cancer." Abstract. *New England Journal of Medicine* (2011).

Scholz, M., Lam, R., Strum, S., and H. Johnson. "Active Surveillance after Induction with Testosterone Inactivating Pharmaceuticals (TIP): Ten Year Outcome." Abstract. *Active Surveillance Symposium* 10 (2007).

Scholz, M., Lam, R., Jennrich, R., Strum, S., Guess, B., and H. Johnson. "Ultra-sensitive PSA Nadir on Testosterone-Inactivating-Pharmaceuticals Accurately Predicts Early Prostate Cancer Progression." Abstract. *Prostate Cancer Symposium* (2006):40.

Lam, R., Scholz, M., Guess, B., Trilling, T., and H. Goodman. "Oral Bisphosphonates Fail to Prevent Bone Loss form Androgen Deprivation Therapy in Men with Prostate Cancer." Abstract. *Prostate Cancer Symposium* (2006):122.

Strum, S., and M. Scholz. "Optimized Imaging in Prostate Cancer is Absent 95% of the Time at Diagnosis or PSA Recurrence." Abstract. *Prostate Cancer Symposium* (2006): 68.

Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., and R.Y. Lam. "Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time-Off Period." *Journal of Urology* (2006): 175.

Scholz, M., Lam, R., Strum, S., Johnson, H., Trilling T., and R. Jennrich. "Intermittent Use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during Testosterone-Recovery Prolongs the Time-Off-Period." Abstract. *Multidisciplinary Prostate Cancer Symposium* (2005): 153.

Lam, R., Scholz, M., Guess, B., Mahoney, J., Johnson, H., Trilling, T., and H. Goodman "Oral Bisphosphonates for the Prevention of Androgen Deprivation Therapy Associated Bone Loss." Abstract. *ASCO* (2004): 4749.

Scholz, M., Johnson, J., Guess, B., and R. Lam. "Extent of Disease on Bone Scan, Baseline Alkaline Phosphatase, and 80% Decline in PSA are the Best Indicators Predicting Long Term Survival in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone." Abstract. *Western AUA* (2003).

Scholz, M., Guess, B., and R. Lam. "Calcitriol Restores Docetaxol Anticancer Activity in Men with Androgen Independent Prostate Cancer Who Previously Progressed on Docetaxol." Abstract. *Western AUA* (2003).

Scholz, M., Guess, B., Barrios, F., Strum, S., and B. Leibowitz. "Low-dose Single-Agent Weekly Taxotere is Effective and Well Tolerated in Elderly Men with Prostate Cancer." Abstract. *ASCO* (2001).

Seltzer, M., Strum, S., Scholz, M., Belldegrun, A., and N. Satyamruthy. "Comparison of Whole Body C-11 Acetate and FDG PET in Patients with Prostate Cancer." Abstract. *Nuclear Medicine* (1999).

Scholz, M., Strum, S., and P. Mittelman. "High-Dose Ketoconazole and Hydrocortisone for Hormone Refractory Prostate Cancer." Abstract. *ASCO* (1999).

Scholz, M., Strum, S., and J. McDermed. "Intermittent Androgen Deprivation (IAD) with Finasteride (F) During Induction and Maintenance Permits Prolonged Time off IAD in Localized Prostate Cancer (LPC)." Presented by Dr. Scholz. *The Journal of Urology* (April 1999).

Scholz, M., and S. Strum. "Phase II Trial of Weekly Low-Dose Taxotere in the Treatment of Patients with Hormone Refractory Prostate Cancer." Abstract. *ASCO* (1999).

Strum, S., and M. Scholz. "A Phase II Trial of Taxotere and Emcyt for Metastatic Prostate Cancer." Abstract. *ASCO* (1999).

Scholz, M., Strum, S., Madsen, L., and J. McDermed. "Intermittent Androgen Deprivation (IAD) Therapy for Prostate Cancer: PSA Response on Cycle 1 Can Predict Response on Subsequent Cycles." ASCO (1999).

Scholz, M., Strum, S., McDermed, J., and L. Madsen. "Intermittent Androgen Deprivation (IAD) with Finasteride Given During the Induction and Maintenance Periods Results in Prolonged Time off IAD in Patients with Localize Prostate Cancer." ASCO (1999).

Scholz, M.C., Strum, S.B, and J.E. McDermed. "A Phase II Trial of Taxotere (t)/Estramustine (e) Combination in P(pts) with Prostate Cancer (pc). Accepted for publication at ASCO (1998).

Scholz, M.C., McDermed, J.E., and S.B. Strum. "Intermittent Hormone Blockade (IHB): Optimal Induction Duration and Predictive Factors for Prolonged time Off Hormone Blockade (HB)." Poster presented at the Xth International Congress on Hormonal Steroids (1998).

Scholz, M.C., McDermed, J.E., and S.B. Strum. "Combined Hormone Blockade (CHB) Induction and Finasteride Maintenance (FM) Permits Discontinuation of CHB for Prolonged Periods in Patients with Low-Volume (LV) Prostate Cancer (PC)." Abstract. *Xth International Congress on Hormonal Steroids* (1998).

Tisman, G., Strum, S.B., Scholz, M.C., et al. "Computer Assisted, Tumor Volume-Based Decision Making in Expectant Management of Early Stage Prostate Cancer. Abstract. *AUA* (1997): 1480.

Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and H. Johnson. "Prolonged Non-Detectable PSA (NDPSA) in Patients (PTS) Receiving Combination Hormone Blockade (CHB) Allows for Discontinuation of Androgen Blockade." Abstract. *AUA* (1997): 1478.

Strum, S.B., Scholz, M.C. and J.E. McDermed. "The Androgen Deprivation Syndrome: the Incidence and Severity in Prostate Cancer Patients Receiving Hormone Blockade." Abstract. ASCO (1998).

Strum, S.B. and M.C. Scholz. "Intermittent Hormone Blockade (IHB) in Prostate Cancer (PC) Patients: Duration of Non-Detectable PSA (NDPSA) on Androgen Blockade Relates to Time Off Treatment." Abstract. *7th International Congress on Anti-Cancer Treatment*. (1997).

Tisman, G., Strum S.B., Scholz, M.C., et al. "Pre-therapy Prediction of the Duration of Post-Therapy Non Detectable PSA for Prostate Cancer Patients Considering Intermittent Combine Hormonal Blockade." Abstract. ASCO. (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. "Anemia Associated with Androgen Deprivation (AAAD) Due to Combination Hormone Blockade (CHB) Responds to Recombinant Human Erythropoietin (r hu-EPO)." Abstact. *AUA* (1997): 1483.

Strum, S.B., McDermed, J.E., Scholz, M.C. et al. "Anemia Associated with Androgen Deprivation (AAAD) in Prostate Cancer (PC) Patients (PTS) Receiving Combination Hormone Blockade (CHB)." ASCO (1997): 16, 345a.

Strum, S.B., McDermed, J., Scholz, M.C., et al. "Time to Non-Detectable (TTND) PSA in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB) Predicts Favorable Outcomes." ASCO (1997): 16, 345a.

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. "Anemia Associated with Androgen Deprivation (AAAD) Due to Combination Hormone Blockade (CHB) Responds to Recombinant Human Erythropoietin (r hu-EPO)." Abstract. *Journal of Urology* (1997): 157, 232.

Tisman, G., Strum, S.B., Scholz, M.C., and J. McDermed. "Pre-Therapy Prediction of the Duration of Post-Therapy Non-Detectable PSA for Prostate Cancer Patients Considering Intermittent Combined Hormone Blockade by Use of Computerized Neural Net Modeling. Abstract. ASCO (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. "Intermittent Hormone Blockade (IHB) in Prostate Cancer (PC) Patients (PTS): Duration of Non-Detectable PSA (NDPSA) on Androgen Blockade Relates to Time off Treatment. Abstract. 7th International Chemotherapy Congress (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Johnson, H.J., and G. Tisman. "Anemia Associated with Androgen Deprivation (AAD) in Prostate Cancer (PC) Patients (PTS) Receiving Combination Hormone Blockade (CHB)." Abstract. ASCO (1997).

Strum, S., McDermed, J., Scholz, M.C., and G. Tisman. "Time to Non-detectable (TTND) PSA in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB) Predicts Favorable Outcomes." Abstract. ASCO (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. Anemia Associated with Androgen Deprivation in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB). Abstract. AUA (1997): 1481.

Tisman, G., Strum, S.B., Scholz, M.C., McDermed, J.E., and H. Johnson. "Computer-Assisted, Tumor Volume-Based Decision Making in Expectant Management of Early Stage Prostate Cancer." Abstract. AUA (1997): 1480.

Scholz, M.C., Grunberg, S., Muggia, F.M., Rosen, P., and L. Leishman. "Phase I Study of TMCA." Abstract. AACR.

Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and H. Johnson. "Prolonged Non-Detectable PSA (NDPSA) in Patients (PTS) Receiving Combination Hormone Blockade (CHB) Allows for Discontinuation of Androgen Blockade. Abstract. AUA. (1997): 1478.

Strum, S.B., Scholz, M.C., and M. Strum. "Prolonged Non-Detectable PSA (NDPSA) in PC Patients Treated with Androgen Deprivation may allow for Discontinuation of Hormone Blockade." Poster presented at the International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Abstract (1995).

CME Lectures

Treating Relapsed Disease without Hormonal Therapy, September 2008

Update on Prostate Cancer for Radiation Therapists, June 2008

Taxotere for Prostate Cancer, Los Angeles, Ca., March 2008

Staging for Prostate Cancer, Los Angeles, Ca., September 2007

Treating Testosterone Independent Prostate Cancer, Los Angeles, Ca., October 2006

PSA Nadir Predicts Prostate Cancer Progression, San Diego, Ca., March 2006

Ketoconazole for Treating Prostate Cancer, Washington DC, June 2005

Management of Bone Integrity, Washington DC, June 2005

Newly Diagnosed Prostate Cancer, Los Angeles, Ca., November 2004

Adjuvant Hormone Blockade with Radiation, Universal City, Ca., January 2004

Relapsed Prostate Cancer, Universal City, Ca., January 2004

Hormone Blockade for Prostate Cancer, Burbank, Ca., September 2003
Chemotherapy for Prostate Cancer, Burbank, Ca., September 2003
Androgen Insensitive Prostate Cancer, Hilo, Hi., November 2002
PCRI Conference Moderator, Los Angeles, Ca., October 2002
Treatment of Hormone Resistance, Whittier, Ca., September 2002
Hormone Blockade for Early PC, Los Angeles, Ca., April 2001
PSA Nadir After Hormone Blockade, Vancouver, Canada, March 2001
Hormone Blockade Update, LA Radiological Society, Ca., January 2000
Intermittent Hormone Blockade, Long Beach Convention Center, Ca., July 1999
Proscar & Intermittent Hormone Blockade, AUA Podium presentation, May 1999
Newly Diagnosed Prostate Cancer, Daniel Freeman Marina, Ca., October 1998
Staging Prostate Cancer, Daniel Freeman Marina, Ca., May 1998
Prostate Cancer Overview, Daniel Freeman Memorial Hospital, Ca., November 1997
Early Hormonal Therapy, Santa Monica-UCLA Medical Center, Ca., October 1997
Prostate Cancer Screening, Daniel Freeman Hospital, Marina del Rey, Ca., July 1997
Prostate Cancer Update, St. Joseph's Hospital Burbank, Ca., March 1997
Breast Cancer Update Sherman Oaks Hospital Sherman Oaks, Ca., January 1993

Community Lectures

Best Way to Utilize the Many New Medications Available for Prostate Cancer, Ca., September 2013
Breakthrough in MRI Diagnosis and Treatment of Prostate Cancer Moderator, May 2013
Newly Diagnosed, Fullerton, Ca., June 2012
What You Need to Know About Prostate Cancer, Westlake Village, Ca., August 2012
Caring for Your Bones When You Have Cancer, Santa Monica, Ca., March 2011
Staging and Treatment of Newly Diagnosed Prostate Cancer, Fullerton, Ca., October 2010
Treating Advanced Prostate Cancer, Orange County, Ca., October 2010
Staging Prostate Cancer, Fullerton, Ca., February 2009
Medical and Dietary Treatment of Prostate Cancer, Pasadena, Ca., October 2008
Active Surveillance for Prostate Cancer, Westlake, Ca., September 2008
Prostate Cancer Update, Phoenix, Az., March 2008
Prostate Cancer Roundtable, Las Vegas, Nv., November 2007
Active Surveillance for Prostate Cancer, Fullerton, Ca., August 2007
Taxotere Prolongs Life, Los Angeles, Ca., April 2007
Systemic Therapy for Prostate Cancer, Beverly Hills, Ca., March 2007
Chemotherapy Variation for Prostate Cancer, Reston, Va., October 2006
How Hormone Blockade is Effective Treatment in the Treatment of Prostate Cancer, Reston, Va., October 2006
Triple Hormone Blockade with Proscar, Reston, Va., October 2006
Prostate Cancer, August 2006
Prostate Cancer Update, Santa Monica, Ca., June 2006
Clinical use of Finasteride to Prolong the Time-off Period, Vancouver, Canada, March 2006
A New Perspective: Look Before You Leap, Fullerton, Ca., February 2006
Testosterone Independent Prostate Cancer, Marina del Rey, Ca., January 2006
PSA Relapse after Surgery or Radiation, Honolulu, Hi., November 2005
My Prostate Cancer is Back. What Now? Las Vegas, Nv., October 2005

Don't Let Prostate Cancer Ruin Your Life, El Segundo, Ca., September 2005
Primary Androgen Deprivation, Los Alamos, Nm., April 2005
Cancer de Prostata Recien Diagnosticada, November 2004
Newly Diagnosed Prostate Cancer, Lancaster, Ca., May 2004
Taxotere for Prostate Cancer, Bakersfield, Ca., April 2004
Recurrent Cancer after Radiation, San Jose, Ca., February 2004
Treating Relapsed Prostate Cancer, Fullerton, Ca., January 2004
Treatment of Rising PSA, Las Vegas, Nv., November 2003
Recurrent Prostate Cancer, Maui, Hi., November 2003
Relapsed Prostate Cancer, San Diego, Ca., October 2003
Prostate Cancer Overview, Irvine, Ca., August 2003
Androgen Independent Prostate Cancer, Marina del Rey, Ca., May 2003
Treatment of Hormone Resistance, Phoenix, Az., March 2003
Hormone Blockade Side-effects, Bakersfield, Ca., March 2002
Prostate Cancer Staging, Las Vegas, Nv., January 2002
Watchful Waiting for Prostate Cancer, Ventura, Ca., September 2001
Treatment for Hormone Resistant Prostate Cancer, Oxnard, Ca., June 2001
Predictors of Hormone Resistance, Marina del Rey, Ca., March 2001
Hormone Blockade for Early Stage Prostate Cancer, Bakersfield, Ca., December 2000
Hormone Blockade, How Long Does it Last? Phoenix, Az., November 2000
Prostate Cancer Overview, Santa Monica, Ca., October 2000
Early Stage Prostate Cancer, Marina del Rey, Ca., September 2000
Hormone Resistant Prostate Cancer, Riverside, Ca., June 2000
Newly Diagnosed Prostate Cancer, Palm Springs, Ca., April 2000
New Approaches to Prostate Cancer, Marina del Rey, Ca. March 2000
Treatment of Early Stage Prostate Cancer, Santa Monica, Ca., March 2000
Criteria for Intermittent Hormone Blockade, San Diego, Ca., December 1999
PSA Relapse after Surgery or Radiation, Bakersfield, Ca., October 1999
New Developments in Prostate Cancer, Hacienda Heights, Ca., May 1999
Nutrition and Prostate Cancer, Long Beach, Ca., April 1999
The Androgen Deprivation Syndrome, Laguna Beach, Ca., February 1999
Prostate Cancer Overview, Inglewood, Ca., November 1998
Prostate Cancer Staging, Daniel Freeman Marina Hospital, Ca., September 1998
Alternative Medicine Approaches, Marina del Rey, Ca., May 1998
Hormone Blockade for Early Stage Prostate Cancer, Redondo Beach, Ca., May 1998
Chemotherapy for Prostate Cancer, Riverside Medical Foundation, Ca., October 1997
The Influence of Grief on Health the Lutheran Equipping Conference, September 1997
Adjuvant Chemotherapy, Long Beach Memorial Hospital, Ca., August 1997
Intermittent Hormone Blockade, Brotman Hospital, Culver City, Ca., June 1997
Prostate Cancer Prevention, Monarch Beach, Ca., June 1997
Prostate Cancer Treatment Options, Santa Monica Hospital, Ca., May 1997
Hormone Blockade, Cottage Hospital, Santa Barbara, Ca., April 1997
Advanced Hormone Therapy, Loma Linda Hospital, Loma Linda, Ca., April 1997
Neoadjuvant Hormone Blockade, Bakersfield Medical Center, Ca., November 1996
Early Hormone Therapy, Prostate Support Group, Fullerton, Ca., June 1996
Cancer Overview, Brotman Wellness Center, Culver City, Ca., May 1996

Treatment With Proscar, San Diego Support Group, San Diego, Ca., January 1996
Prostate Cancer Treatment Options, Glantz Auditorium, Culver City, Ca., May 1995
Therapy for Stage D2 Prostate Cancer, Culver City, Ca., October 1995
Treatment of Melanoma Medical, Center of North Hollywood, Ca., October 1993
Nutrition and Cancer Medical, Center of North Hollywood, Ca., March 1993

Conferences

Prostate Cancer Research Institute National Conference, Speaker 2013
Prostate Cancer Research Institute National Conference, Speaker 2012
Image-Guided Diagnosis and Treatment Symposium, Introductory Speaker March 27, 2011
Prostate Cancer Research Institute National Conference, Speaker 2011
Prostate Cancer Foundation of Australia, Speaker 2010
Prostate Cancer Research Institute National Conference Moderator 2007, 2008, 2009, Speaker 2010
Prostate Cancer Research Institute Regional Conference, Moderator 2002, 2004

Educational DVDs

Scholz, Mark, "PCRI Conference 2013", DVD. 2013.

Scholz, Mark, "PCRI Conference 2012", DVD. 2012.

Scholz, Mark, "The Patients' Guide to Active Surveillance for Prostate Cancer", *Medical Instructional Media*, DVD. USA: Medical Instructional Media, 2011.

Scholz, Mark, "PCRI Conference 2011", DVD. 2011.

Scholz, Mark, "PCRI Conference 2010", DVD. 2010.

Scholz, Mark, Richard Lam, and Melody Mendenhall. "My Doc Personalized Patient Information", *Novartis Oncology*, DVD. USA: Novartis, 2009.

Scholz, Mark, "PCRI Conference 2009", DVD. 2009.

Scholz, Mark, "PCRI Conference 2008", DVD. 2008.

Scholz, Mark, "PCRI Conference 2007", DVD. 2007.

Harold Apter, *A New Perspective for Early Stage Disease: Look Before you Leap*, videotape of lecture by Mark Scholz, MD presented at meetings of the Prostate Cancer Support Group, Marina del Rey, January 19, 2006.

Harold Apter, *Testosterone Independent Prostate Cancer*, videotape of lecture by Mark Scholz, MD presented at meetings of the Prostate Cancer Support Group, Marina del Rey, January 19, 2006.

Educational Booklets and Brochures

Prostate Oncology Specialists, Inc., Why Consult a Medical Oncologist, Winter 2011.

Prostate Oncology Specialists, Inc., The Doctor You Choose will Make a Difference, Summer 2005.

What's your Type?

Adjuvant Testosterone Inactivating Pharmaceuticals

Avodart or Proscar for the Treatment of Prostate Cancer

Anti-androgen Monotherapy

Bisphosphonates: Preventing Cancer Spread to the Bones

Family History of Prostate Cancer

How Prostate Cancer Can Extend Your Life

Introduction to Testosterone Inactivating Pharmaceuticals

Introduction to the Treatments for Newly-Diagnosed Prostate Cancer

Osteoporosis

Preventing the Side Effects of Testosterone Inactivation Pharmaceuticals

Surgery vs. Seeds vs. IMRT

Taxotere

The Best Treatment for Prostate Cancer

The PSA Blood Test for Diagnosing Prostate Cancer: Arguments Pro and Con

Newly Diagnosed Prostate Cancer: Evaluating the Options Part I

Newly Diagnosed Prostate Cancer: Evaluating the Options Part II

Newly Diagnosed Prostate Cancer: Evaluating the Options Part III

Adjuvant Testosterone Inactivating Pharmaceuticals

So You Have an Elevated PSA

Recently Diagnosed Prostate Cancer

Explanation of Laboratory Tests

TIP for Early Stage Disease

The Best Treatment for Prostate Cancer

Hormone Blockade for Early Stage Prostate Cancer

Interviews

Newspapers and Magazines

Mark Scholz, interview by Jessica Myers, *A Conversation With Dr. Mark Scholz*, Ask Dr. Myers, The Blog, April 15, 2014.

Mark Scholz, *Omaha doctor on cutting edge of prostate cancer care*, Livewell Nebraska, January 21, 2014.

Mark Scholz, interview by Landon Hall, *Take prostate cancer news with grain of salt, doctor says*, OC Register, May 30, 2013.

Mark Scholz, *Dr. Mark Scholz on Advances in Prostate Cancer Imaging*, OncLive, May 10, 2013.

Mark Scholz, *Dr Mark Scholz : « Les opérations inutiles de la prostate sont une tragédie. »*, La Nutrition.fa, January 6, 2012.

Mark Scholz, *Prostate-test advice scorned by some docs*, The Columbus Dispatch, October 13, 2011.

Mark Scholz, interview by Paul Chavez, *Marina del Rey Prostate Cancer Specialist Says New Treatment Offers Hope for Patients*, September 21, 2011.

Mark Scholz, *There Will Be Pricks*, Slate, November 24, 2010.

Mark Scholz, *Prostate Cancer: When to Cut, When to Cut and Run*, Reporters Notebook, November 19, 2010.

Mark Scholz, interview by Joyce Frieden, *Medicare Panel Gives Tentative Nod to Prostate CA Drug*, MedPage Today, November 18, 2010.

Mark Scholz, interview by Susan Heavy, *U.S. Panel Backs Dendreon's Provenge for Medicare*, Reuters, November 17, 2010.

Mark Scholz, *Medicare Advisory Panel Reviews Data on Provenge*, November 17, 2010.

Mark Scholz, interview by Nick Mulcahy, *FDA Adds Heart Disease, Diabetes Warnings to GnRH Agonist Labels*, October 20, 2010.

Mark Scholz, interview by Kirkham Hamilton, *Prostate Cancer: Invasion of the Prostate Snatchers*, October 14, 2010.

Mark Scholz, *Prostate Cancer Calls for Better Early Detection and Treatment*, Science News, September 17, 2010.

Mark Scholz, interview by Deborah Kitz, *Skip the PSA Test for Prostate Cancer: New Research Suggests Screening Shouldn't be Routine but May Be Useful for Some Men*, US News World and Report, September 15, 2010.

Mark Scholz, *A Rush to Operating Rooms that Alters Men's Lives*, New York Times, August 30, 2010.

Mark Scholz, *Prostate Surgery can Lead to Impotency*, TopNews, August 9, 2010.

Mark Scholz, *Tests and tools to live long and live well. Plus: the prostate debate*, Newsweek, June 18, 2010.

Mark Scholz, *Prostate Surgery Warning: You May Do Just as Well with Safer Options, But Few Men are Being Told About Them*, Bottom Line Health, 2010.

Mark Scholz, interview by Kirkham Hamilton, *Prostate Cancer Treated as a Chronic Disease One Oncologist's Approach*, September 30, 2009.

Mark Scholz, interview by Susan Brink, *Prostate Cancer Test's Accuracy Cited*, Los Angeles Times, April 26, 2007.

Mark Scholz, interview by Ryan Ferrier, *Quality Control: Methods for Managing Pain*, RT Image, July 10, 2006.

Mark Scholz, interview by Amy Storer, *RT Image Dying to Live*, RT Image, July 10, 2006.

Mark Scholz, interview by Susan Brink, *Act? Wait? It Can Be Your Choice*, Los Angeles Times Health, July 3, 2006.

Mark Scholz, interview by Josh Marks, *Dr. Mark Scholz is a Man on a Mission*, Santa Monica Observer, December 5, 2005.

Mark Scholz, interview by Lee Peterson, *Prostate Cancer Patients Asked to Weigh Treatments*, Daily Breeze October 10, 2005.

Mark Scholz, *Prostate Cancer Seminar Present Treatment Options*, Daily News, September 15, 2005.

Mark Scholz, *Prostate Cancer: the (not so) Simple Facts*, Men's Health, 2005.

News Releases

CNBC, "Google+ Hangout Discussion Today with Prostate Specialist, Mark Scholz, MD and Wirebuzz.com for International Men's Health Month," news release, 14 June 2013. <http://www.cnbc.com/id/100817005>

Ventura County Star, "Task force: Cancer may be bad, treatment may be worse," news release, 24 June 2012. <http://www.vcstar.com/news/2012/jun/24/task-force-cancer-may-be-bad-treatment-may-be/>

AdMeTech Foundation, "ABC TV Hit Dancing with the Stars' Celebrities Support Prostate Cancer Awareness," news release, 9 September 2011. <http://www.prnewswire.com/news-releases/abc-tv-hit-dancing-with-the-stars-celebrities-support-prostate-cancer-awareness-129525363.html>

Prostate Oncology Specialists, "Prostate Oncology Specialists Congratulates Dr. Richard Lam Named in Super Doctors®," news release, 16 August 2011. <http://www.prnewswire.com/news-releases/prostate-oncology-specialists-congratulates-dr-richard-lam-named-in-super-doctors-127888053.html>

Prostate Oncology Specialists, "Prostate Oncology Specialists, Inc. Launches Prostate Snatchers - A Blog Featuring Posts by the Co-Authors of Invasion of the Prostate Snatchers," news release, 29 March 2011. <http://www.prnewswire.com/news-releases/prostate-oncology-specialists-inc-launches-prostate-snatchers---a-blog-featuring-posts-by-the-co-authors-of-invasion-of-the-prostate-snatchers-118887209.html>

Prostate Oncology Specialists, "Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients with PROVENGE," news release, 27 October 2010. <http://www.prnewswire.com/news-releases/photos/prostate-oncology-specialists-among-first-in-the-nation-to-treat-advanced-prostate-cancer-patients-with-provenge-105890468.html>

Radio

Mark Scholz, interview by Pat Campbell, *The Pat Campbell Show*, KFAQ, October 17, 2011.

Mark Scholz, interview by Jerry Doyle, *The Jerry Doyle Show*, Talk Radio Network, October 11, 2011.

Mark Scholz, interview by Bob Barrett and Nina Sax, *The Health Show*, WAMC-AM, October 6, 2011.

Mark Scholz, interview by Carole Marks and Michael Harrison, *A Touch of Grey*, October 4, 2011.

Mark Scholz, interview by Samir Taneja and Herb Lepor, *Men's Health*, Sirius XM Radio, September 28, 2011.

Mark Scholz, interview by Don Wagner, *Dr. Don Show*, KZZZ-AM, September 7, 2011.

Mark Scholz, interview by Michael Dresser, *Dresser After Dark*, BBS Radio, September 6, 2011.

Mark Scholz, interview by Mark Johnson, *Mark Johnson Show*, WDEV-AM, August 30, 2011.

Mark Scholz, interview by Dr. Israel Barken, PC-REF, August 30, 2011.

Mark Scholz, interview with Newsmax, October 18, 2010.

Mark Scholz, interview by Ronald Hoffman, *Health Talk with Dr. Ronald Hoffman*, WOR radio, September 2, 2010.

Mark Scholz, interview by Deborah Kotz, *US News & Report*, August 4, 2010.

Mark Scholz, *Danny Watson Show, Newstalk ZB*, August 1, 2010.

Mark Scholz, interview by Ronald Hoffman, *Health Talk with Dr. Ronald Hoffman*, WOR radio, July 23, 2010.

Mark Scholz, interview by Dr. Israel Barken, *PC-REF*, 2010.

Mark Scholz, *Staying Healthy Today Radio, Prescription 2000*, October 12, 2009.

Television and Videos

"Invasion of the Prostate Snatchers with Mark Scholz", *This Week in Oncology*. 28 August 2012.

"Living with Advanced Prostate Cancer (ROYAL shade)", *YouTube PCRI Channel*. 25 July 2012.

"Breast Cancer Screening May Cause More Harm Than Good, Study Finds" *GMA Health, ABC News*, 8 December 2011.

"Blue September, The Oakland Raiders and Mark Scholz, MD." *YouTube Blue September Channel*. 25 August 2010. Television.

"Sesno Reports: Cancer Cures? 'Harry's Story'", *PBS Sesno Reports*. PBS. 8 September 2010. Television.

Mark Scholz, interview by Pippa Wetzell, *Breakfast News, TVNZ*, August 10, 2010.

Mark Scholz, *Inside E Street*, PBS, May 2, 2011.

Mark Scholz, interview by Jack Hanson, *Newsmaker, Comcast*, 2010.

Mark Scholz, *PBS Sesno Reports – 'Cancer Cures: Harry's Story'*, PBS, 2010.

Books

Mark Scholz, MD and Ralph H. Blum, *Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Sexual Potency* (New York, NY: Other Press, 2010). Hardback.

Mark Scholz, MD and Ralph H. Blum, *Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Sexual Potency* (New York, NY: Other Press, 2011). Paperback.

Mark Scholz, MD and Ralph H. Blum. 2010. *Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Sexual Potency*. New York [New York]: Other Press. <http://www.otherpress.com/books>. Electronic book. (Also available in print form).

Recognition and Awards

Nautilus Book Award Gold Winner in Wellness/Prevention/Vitality, 2011. Ralph H. Blum, Mark Scholz, MD.

Best Poster Western AUA 2003: *PSA Nadir Greater than 0.1 on Combined Hormone Blockade Predicts the Early Development of Androgen Independent Prostate Cancer.* Mark C. Scholz, Tom Trilling, Stan A. Brosman, Brad W. Guess, Henry J. Johnson, Richard Y. Lam.

Best Poster AUA 1997: *Anemia Associated with Androgen Deprivation in Prostate Cancer Patients on Combination Hormone Blockade.* Stephen B. Strum, John E. McDermed, Mark C. Scholz.